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Does Anatomical Segmentectomy Allow an Adequate
Lymph Node Staging for cT1a Non-small Cell Lung
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Sandro Mattioli, MD,* Alberto Ruffato, MD, PhD,* Francesco Puma, MD,†
Niccolo` Daddi, MD, PhD,† Beatrice Aramini, MD,‡ and Frank D’Ovidio, MD, PhD§
Introduction: Anatomical segmentectomy is again under evaluation
for the cure of T1a N0 non-small cell lung cancer and carcinoid
tumors. Whether anatomical segmentectomy does permit or not, an
adequate resection of nodal stations for staging or cure is still
pending.
Methods: A case-matched study was ruled on patients with periph-
eral cT1a N0 M0 tumors that underwent anatomical segmentectomy
or lobectomy. Dissection of lymph node stations 4, 5, 6, and 7 was
identical in anatomical segmentectomy and lobectomy; stations 10,
11, 12, and 13 were also dissected carefully during anatomical
segmentectomy.
Results: We individually matched 46 (69% men) anatomical seg-
mentectomy with 46 (71% men) lobectomy for age, anatomical
segment, and size of the tumor. The median (interquartile range) size
of the resected lesions was 1.7 cm (1.35–1.95 cm) in anatomical
segmentectomy and 1.6 cm (1.3–1.9 cm) (p  0.96) in lobectomy.
The anatomical segmentectomy and lobectomy resection margins
were free of cancer. The median number (interquartile range) of total
dissected lymph nodes was 12 (8–5–14) in anatomical segmentec-
tomy compared with 13 (12–14.5) in lobectomy (p  0.68), with a
number of N1 nodes being 6 (4–7.5) and 7 (4.5–9.5) (p  0.43),
respectively, and N2 nodes 5.5 (4–7.7) and 5 (4–6.5) (p  0.88).
Only 1 patient of 46 (2%) anatomical segmentectomy was N1,
whereas in lobectomy, 4% had N1 (2 patients). Freedom from
recurrence at 36 months was 100% for anatomical segmentectomy
and 93.5% for lobectomy (p  0.33).
Conclusions: Anatomical segmentectomy for cT1a tumors com-
pared with lobectomy procures an adequate number of N1 and N2
nodes for pathological examination. Cancer-specific survival was
equivalent at 36 months.
Key Words: Non-small cell lung cancer, Sublobar lung resections,
Lung segmentectomy, Lymph node staging.
(J Thorac Oncol. 2011;6: 1537–1541)
The efficacy of sublobar resections for the therapy fornon-small cell lung cancer (NSCLC) is debated since a
long time. One of the cornerstones on this topic, the multi-
center study run by the NSCLC Study Group in the early 90s
in patients affected by peripheral clinical T1 N0 NSCLC, did
demonstrate higher local recurrence rate and a trend toward
poorer survival in patients in whom a sublobar resection was
performed, with respect to patients submitted to standard
lobectomy.1 Whether to spare lung tissue is worth in terms of
lung function and it is not detrimental on the cure of NSCLC
is the core of the discussion.
Today, the routine adoption of multislice computed
tomography (CT) scan for the study of lungs and mediasti-
num has increased the number of patients undergoing primary
surgical therapy for NSCLC tumors smaller than 1–2 cm.2,3
An improvement in survival for patients with lesions of this
size has been shown, supporting the hypothesis that smaller
lesions are likely to represent earlier stage and potentially
more curable disease.4 These observations are confirmed by
the multicentric analysis performed for the elaboration of the
seventh edition of the tumor-node-metastasis classification of
lung cancer that proposes a separate substage for lesions of 2
cm or less in size.5
The incidence of second primary lung cancer may be
approximately 3% per year6; thus patients who survive 5 or
more years after their first resection would face a significant
cumulative danger of second cancers. With this perspective,
any sparing of lung tissue and respiratory reserve may be
important if the cure of cancer remains totally effective.
Recently, the studies by Okada et al.7 and Koike and cowork-
ers8–10 have supported the role of anatomical segmentectomy
reporting data of survival and local recurrence rates equiva-
lent to lobectomy for stage IA tumors of 2 cm or less.11
However, the effectiveness of segmentectomy in place
of lobectomy is not yet assessed.12 Among the numerous
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aspects needing clarification, we focused on the extension of
lymphadenectomy, in terms of staging and curative potential,
for which limited information is available.13
The purpose of our retrospective investigation was to
compare anatomical segmentectomy and lobectomy for NSCLC
lesions measured as 2 cm or less on the preoperative CT scan
film, with regard to the number/station of lymph nodes resected.
Survivals of the two groups were also considered.
MATERIALS AND METHODS
We included in the study 46 (69% men; median age 72
years, interquartile range [IQR] 62–77 years) intentional
anatomical segmentectomies with systematic nodal dissection
individually matched with 46 (71% men; median age 73
years, IQR 67.5–76 years) lobar resection associated with
systematic nodal dissection performed for patients with pe-
ripheral cT1a N0 M0 NSCLC. The size of the lesion was
measured on the preoperative CT scan films. Preoperative
staging included history and physical examination, CT of the
brain, chest, upper abdomen, tracheal broncoscopy, positron
emission tomography (PET), or CT-PET scan. Mediastinos-
copy was not used routinely in preoperative evaluation of
stage IA patients. None had received neoadjuvant therapy.
All patients included in the study were able to tolerate
at least a lobectomy as evaluated by cardiopulmonary func-
tional tests and had no history of previously treated cancer.
Patients were recruited in the segmentectomy and lobectomy
groups in different ways. Starting in January 2001, we offered
anatomical segmentectomy as an alternative to lobectomy to
patients affected by a peripheral cT1a N0 M0 NSCLC. We
discussed with patients the two surgical options available and
the pros and cons in light of the actual knowledge of the
scientific community in this field, and informed consent for
anatomical segmentectomy was obtained.
The cases in whom lobectomy was performed within
the same time period were retrospectively retrieved from the
institutional electronic medical record system database rou-
tinely in use in our division and in the division of thoracic
surgery of the University of Perugia. The institutional review
boards of the University of Bologna and the University of
Perugia approved the use of the databases from the two
Divisions of Thoracic Surgery for research purposes.
This database was specifically designed and updated for
patients with lung cancer. The coordinates considered by the
automatic selection of the cases inside the database were
diameter of the nodule, peripheral location, and standard
lobectomy. A pool of 357 patients underwent a lobectomy for
a T1 lesion within the investigated period; 89 patients from
this group presented a clinical lesion of 2 cm or less in greater
dimension. A paired matching analysis for age, anatomical
segment, and size of the tumor was performed for patients
from the lobectomy group: 46 patients with homogeneous
clinical features were identified and individually matched to
patients who underwent segmentectomy.
The resected tumors were classified according to the
current International Union Against Cancer tumor-node-me-
tastasis classification.14
Segment localization, tumor size, tumor histotype, grad-
ing, and histology comprehensive of the assessment of the
bronchial resection margin of the segmental plan and the
visceral pleura were recorded. Segment localizations were
reported using numbers 1–10 according to the definition of
Boyden.15 Follow-up was inclusive of serum markers, chest
x-ray, and abdominal ultra sound every 6 months and on
yearly PET or CT-PET scan for at least 5 years after surgery.
Time of relapse and causes of death were recorded.
Operation
The approach for the resection of cT1a N0 M0 NSCLC
was an axillary muscle-sparing thoracotomy. In case of seg-
mentectomy, when preoperative histology had not been pre-
viously obtained, to preserve the segmental anatomy, a tru-
cut biopsy of the nodule was taken with a TEMNO 16-gauge
20 cm automatic disposable needle (Cardinal Health, Inc.
Dublin, OH), and the tissue carrot was sent for frozen section
examination. Segmentectomy involved dissecting out the
hilar structures and securing the branches of the pulmonary
artery, pulmonary vein, and segmental bronchus individually.
After clamping the segmental bronchus, care was taken to
partially inflate the lung before parenchymal resection to
assist in identifying the appropriate boundaries of resection.
The surgeon compressed the parenchyma with the fingers
placed as clamps to decrease the intersegmental ventilation or
vice versa; if the limits of the segment were not well local-
ized, the lung was deflated and usually the segment in which
bronchus was clamped remained inflated longer. The seg-
mental plane was then appreciated with a tactile sensation
while lifting up the segmental bronchus, and the intersegmen-
tal plane is dissected bluntly after identifying the interseg-
mental vein net, which must be carefully preserved. If there
were any findings suggesting that segmentectomy was not
suitable because the location of the nodule was too near to the
adjacent segments, the resection margins were examined by
the pathologists during the operation, and the operation was
modified accordingly to an extended segmentectomy, in
which the resection line could be placed on the adjacent
segment or portions of few adjacent segments, or to a lobec-
tomy. Both lobectomy and segmentectomy were completed
with a systematic lymphadenectomy.16 Radical dissection of
lymph node stations 4, 5, 6, and 7 was identical in segmen-
tectomies and lobectomies. Node stations 10, 11, 12 and the
segmental 13 were also dissected carefully during segmen-
tectomy and in the pathology laboratory after lobectomy.
Postoperative care was similar after segmentectomy and lobar
resection.
Statistical Analysis
A paired matching analysis for age, segment, and size
of the tumor has been performed to identify patients in the
lobectomy control group. Continuous variables such as age,
tumor size, number of dissected lymph nodes, and follow-up
duration are expressed as median and IQR. Differences be-
tween the groups of segmentectomies and lobectomies ac-
cording to continuous variables were assessed by the Wil-
coxon test for paired data. The associations between the
clinicopathologic characteristics within the two types of re-
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sections were analyzed by the use of a contingency table.
Statistical significance was evaluated using the 2 test. Can-
cer-specific survival rate was calculated including recurrence
and deaths because of recorded recurrence. The statistical
analysis was performed by applying the actuarial (life table)
method and compared by the Wilcoxon (Gehan) test. No
Bonferroni correction was performed. A p value less than
0.05 was considered significant. Statistical analyses were
performed using a SPSS 13.0 software package (SPSS Inc.,
Chicago, IL).
RESULTS
No perioperative mortality was observed. Complica-
tions occurred in 13% (6/46) of segmentectomies (acute renal
failure in one patient, air leak for more than 6 days in two
patients, residual cavity in two patients, and atrial fibrillation
in one patient) and in 15% (7/46) of lobectomies (air leak for
6 days in one patient, residual cavity in two patients,
reoperation for bleeding in one patient, pleural effusion in
one patient, and atrial fibrillation in two patients), but a
significant difference between the two groups was not de-
tected (p 0.76). The median follow-up was 25 months (IQR
16.5–58.5) for the segmentectomy group and 32 months (IQR
17.8–55.5) for the lobectomy group. Seven patients died for
causes unrelated to NSCLC, four in the segmentectomy
group and three in the lobectomy group. Two patients of the
lobectomy group presented a locoregional recurrence, and
one patient presented a distant cutaneous recurrence in the
right thigh. The median tumor size in the segmentectomies
was 1.7 cm (IQR 1.35–1.95 cm) and 1.6 cm (IQR 1.3–1.9 cm)
in the lobectomy group (p  0.96). In one patient, cytology
of the segmental plane was positive, and the segmental
resection (left S7) was extended to the adjacent segment. The
histological types are summarized in Table 1; there were no
significant differences between the two groups according to
tumor histology (p  0.83). In Table 2 the types of segmen-
tectomy performed are reported. The distribution of resec-
tions between the two lungs was homogeneous; the localiza-
tion of the lesions involved in most cases the upper lobes. The
preoperative characteristics and operative details of the two
groups were very similar as a result of the matching process.
The number of dissected lymph nodes in segmentecto-
mies was 500 lymph nodes (median of 12, IQR 8.5–14)
compared with 599 (median 13, IQR 12–14.5) lymph nodes
available for pathological assessment after lobar resections
(p  0.68). In Table 3, the details of the mean number of the
dissected lymph nodes according to the location—side of
lung (stations 5 and 6) are given. Stations 11–13 (N1) were
grouped. The statistical comparison of the number of nodes
resected was calculated on median values for N1 and N2
stations. We obtained a median number of 6 (IQR 4–7.5)
nodes from N1 stations after anatomical segmentectomy
compared with 7 (IQR 4.5–9.5) N1 nodes after lobectomy
(p  0.43). No differences were also detected comparing the
median number of nodes from N2 stations available for
pathological evaluation after segmentectomies 5.5 (IQR
4–7.7) and after lobectomies 5 (IQR 4–6.5) (p  0.88).
Table 4 summarizes the pathologic staging of cases.
Most of the segmentectomies (96%) where p stage IA; in 1
patient (2%) a p stage IB (pT2 visceral pleural involvement)
was detected and in 1 patient (2%) a p stage IIB (pT2 visceral
pleural involvement with 1 out of 15 N1 positive node) was
detected. In the lobectomy group, two patients (4%) pre-
sented visceral pleural involvement with p-stage IB and two
TABLE 2. Tumor Location by Type of Procedure
Right Lung Left Lung
Segmentec
Tomies
Lobec
Tomies
Segmentec
Tomies
Lobec
Tomies
Upper lobe 8 S1–2 9 S1–2 14
5 S1 17 5 S4–5
4 S3
Middle lobe
Lower lobe 3 S8–9 5 S6 6
1 S10 9 1 S7
5 S6
Total 26 26 20 20
TABLE 3. Extension of Lymph Node Dissection by Type of
Procedure
Segmentectomies
LN Stations
Lobectomies
No. Median No. Median
161 3 11–12–13 218 3
98 2 10 123 2.5
13 0.5 9–8 69 1
53 2 7 50 1
24 0.5 6 24 0.5
61 3 5 36 1.5
83 3 4 70 2
7 0 3–2 9 1
500 12 599 13
TABLE 4. Pathological Staging by Type of Procedure
Segmentectomies Lobectomies
p stage Ia 44/46 (96%) Ia 42/46 (92%)
Ib (pleural inv.) 1/46 (2%) Ib (pleural inv.) 2/46 (4%)
IIb (pleural inv. and 1 N1 node)
1/46 (2%)
IIa 3 (T1N1Mx) 2/46 (4%)
pN status pN0 45/46 (98%) pN0 44/46 (96%)
pN1 1/46 (2%) pN1 2/46 (4%)
TABLE 1. Pathologic Assessment of the Lesions by Type of
Procedure
Histology Segmentectomies Lobectomies p
Adenocarcinoma 25 (54%) 23 (50%) 0.832
Squamous cell carcinoma 15 (33%) 15 (33%)
Miscellaneousa 6 (13%) 8 (17%)
a Miscellaneous: 11 bronchoalveolar carcinomas and 3 typical carcinoids.
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patients (4%) presented an N1 involvement with p-stage IIA.
In detail, nodal involvement was in one patient (G3 adeno-
carcinoma) a station 11 node metastasis and in one patient
(G2 squamous cell carcinoma) a station 10 node metastasis.
No differences were detected in the 36 months actu-
arial freedom from cancer survival rate of patients who
underwent segmentectomy (100%) comparing with pa-
tients who underwent lobar resection (93.5%) (Wilcoxon
[Gehan] test, p  0.33).
DISCUSSION
Although lobectomy is still considered the procedure of
choice for any primary NSCLC, an increasing number of
clinical studies are reevaluating the effective role of this
procedure for lesions up to 2 cm in diameter (maximum) with
absence of nodal involvement at the preoperative work up.
With the unrelenting improvement of imaging techniques, the
frequency in the diagnosis of small pulmonary nodules is
increasing and the appropriateness of the surgical option that
can be proposed to obtain the best therapeutic effect needs to
be rediscussed.
When considering anatomic segmentectomy to replace
the standard lobectomy as a curative resection strategy for
cT1a N0 M0 NSCLC, there are several key points that need
to be clarified:
1. Does the benefit of sparing lung parenchyma and there-
fore respiratory function (considering the potential risk
of a new primary NSCLC in patients surviving to the
first tumor) outweigh the greater complexity of an ana-
tomical segmentectomy compared with lobectomy17? Is
the functional result the same if a soft intersegmental plain
is preserved or it is compressed in a rigid staple line?
Moreover, in case of segmentectomy, when the nature of
the nodule has not been assessed preoperatively, dedicated
intraoperative biopsy techniques of the tumor may be
advised to preserve the anatomy of the lung and perform
correctly the segmentectomy.
2. Is segmentectomy as valid as lobectomy from an onco-
logical point of view? We focused our attention on the
second point and, in particular, on the extent of lymph-
adenectomy. Okada et al.18 evaluated the effect of tumor
size on prognosis after resection of 1272 patients. There
was no statistical difference in 5-year disease-free survival
in lobectomy or segmentectomy patients with tumors 2 cm
or less in diameter (87.4% versus 84.6%, respectively).
In another study by Fernando et al.,19 lobar and sublo-
bar resections were compared in patients with T1 tumors.
Survival was similar in patients undergoing lobar or sublobar
resection for tumors less than 2 cm, whereas it was signifi-
cantly longer in the lobar group in patients with tumors of 2
to 3 cm. Other reports examining sublobar resection in the
setting of subcentimetric tumors document no difference in
local recurrence or survival.10,20 These data support the
evolving concept that anatomical segmentectomy can be
performed with similar expected survival in selected patients
with small peripheral tumors, in particular those smaller than
2 cm.
Limited information is available evaluating accurately
the nodal status of patients who underwent an anatomical
segmentectomy for small NSCLC; only few experiences
analyzed carefully the extension of the lymph node dissection
performed during segmentectomy. In the article by Schuchert
et al.,21 fewer lymph nodes were harvested on average during
segmentectomy compared with lobectomy (8.1 versus 14.8;
p  0.001) on stage IA and B patients. This difference was
referred as principally due to the smaller specimen obtained
during segmentectomy, but no information on the location
and number of nodal stations sampled between the segmen-
tectomy and lobectomy groups were reported. In their expe-
rience, overall recurrence rates were similar between segmen-
tectomy (17.6%) and lobectomy (16.7%) groups, and most
recurrences were seen in stage IB patients. There may be a
tendency to understage patients if adequate lymph node
dissection is not performed. In another study,13 patients
receiving sublobar resection were much more likely to have
limited lymph node sampling. Forty-three percent (83 of 191)
of the sublobar patients did not have a single node sampled
compared with only 2.7% of lobectomy patients. More than
half of the lobectomy patients had extensive (8 or more)
nodes removed, whereas only 38 of 191 (20%) sublobar
patients had the same. In this report, patients were included in
stage I; however, tumor under staging for patients undergoing
sublobar resection could not be excluded as a consequence of
the difference in the extent of lymph node dissection between
lobectomy and sublobar resection. Their analysis showed a
2% decrease in the risk of dying for every node that was
resected and possibly resulted in a bias in survival favoring
lobectomy.
The lack of differentiation between N1 and N2 nodal
stations could have biased the determination of higher rate of
recurrence after anatomical segmentectomy with respect to
lobectomy.
Anatomical segmentectomy provides for pathology
more nodes than the wedge resection. In two recent studies
performed by Sienel et al.,22,23 56 patients underwent seg-
mentectomy with systematic nodal dissection and 31 under-
went wedge resection with selective nodal sampling at the
surgeon’s discretion for stage I NSCLC. The mean number of
resected lymph nodes was statistically different (6 in wedge
resections and 12 in segmentectomies). Segmentectomy was
associated with longer cancer-related 5-year survival com-
pared with wedge resection (71% and 48%, respectively).
Local recurrence was significantly lower in segmentectomy
(16%) than in wedge resection (55%), although in the mul-
tivariate analysis type of resection, age and tumor size were
the only significant prognostic factors.
In our study, if compared with standard lobectomy,
anatomical segmentectomy for cT1a N0 M0, NSCLC pro-
vided a lower number of N1 nodes (259 versus 341) and the
same number of N2 nodes (241 versus 258) for pathological
examination. However, the comparison according to median
values did not show any statistical difference between seg-
mentectomy and lobectomy for N1 and N2 nodes. It is also
worth to note that the number of dissected lymph nodes in
anatomical segmentectomies (mean of 11.4  3.5) fully
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accomplishes the limit of six lymph nodes necessary to
accurately define the nodal staging according to the European
Society of Thoracic Surgeons (ESTS)-International Union
Against Cancer guidelines and criteria for intraoperative
nodal staging.24 The number of nodes resected in the N2 zone
depends on the beliefs of the surgeon and not on lobectomy
or segmentectomy. We performed routinely a radical N2
station dissection.
In conclusion, the present study underlines a very
specific but not secondary aspect of segmental resections of
the lungs for the therapy for NSCLC. Further research will be
necessary to clarify if it is worth or not to extend the
interlobar nodes dissection in course of segmentectomy to the
nonresected segments as stated by Nomori et al.25 on the basis
of their experience with intraoperative sentinel node identi-
fication. Hopefully, new data will be also collected on the
definitive effects on respiratory function and on the long-term
survival of segmentectomy with respect to lobectomy. Tech-
nique and science move on in synergy; in view of a better
cure for our patients, it is possible that in the next future an
old operation ideated for the cure of tuberculosis will need
restyling for the cure of lung cancer.
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